10.1038/ng1196-361 [DOI] [PubMed] [Google Scholar] Shigenaga M.K., Hagen T.M., and Ames B.N
Did you know that approximately 20% of people taking Ozempic experience nausea, with other gastrointestinal disturbances like vomiting and diarrhea affecting many more
In preclinical studies, BPC-157 demonstrated an exceptionally wide therapeutic window with no observed toxicity even at high doses. Sikiric et al., Current Pharmaceutical Design Long-Term Safety As of now, long-term human safety data is lacking
Developed by Eli Lilly, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors a mechanism that may offer advantages for weight management, metabolic health, and conditions such as polycystic ovary syndrome (PCOS) that disproportionately affect women
Semaglutide users often carry higher baseline vascular risk
Peptide GLP-1 agonists require complex solid-phase peptide synthesis, extensive purification, and cold-chain distribution infrastructure